PepGen Announces First Participant Dosed in a Phase I Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen, Inc. announced a critical clinical milestone for PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.